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Abstract: 
Background: Depression is one of the major contributors to poorer quality of life 
amongst individuals with psychosis and schizophrenia. The study was designed as a Pilot 
Trial to determine the parameters of a larger, definitive pragmatic multi-centre 
randomised controlled trial of Acceptance and Commitment Therapy for depression after 
psychosis (ACTdp) for individuals with a diagnosis of schizophrenia who also meet 
diagnostic criteria for major depression. 
Methods: Participants were required to meet criteria for schizophrenia and major 
depression. Blinded follow-ups were undertaken at 5-months (end of treatment) and at 
10-months (5-months post treatment). Primary outcomes were depression as measured 
by the Calgary Depression Scale for Schizophrenia (CDSS) and the Beck Depression 
Inventory (BDI). 
Results: A total of 29 participants were randomized to ACTdp + Standard Care (SC) 
(n=15) or SC alone (n=14). We did not observe significant differences between groups 
on the CDSS total score at 5-months (Coeff=-1.43, 95%CI -5.17,2.32, p=0.45) or at 10-
months (Coeff=1.8, 95%CI -2.10, 5.69, p=0.36). In terms of BDI, we noted a 
statistically significant effect in favour of ACTdp+SC at 5-months (Coeff=-8.38, 95%CI -
15.49, -1.27, p=0.02) but not at 10-months (Coeff=-4.85, 95%CI -12.10, 2.39, 
p=0.18). We also observed significant effects on psychological flexibility at 5-months 
(Coeff=-0.883, 95%CI -14.94, -2.71, p<0.01) but not 10-months (Coeff=-4.92, 95%CI 
-11.09, 1.25, p=0.11).  
Implications: In this first RCT of a psychological therapy with depression as the primary 
outcome, ACT is a promising intervention for depression in the context of psychosis. A 
further large-scale definitive randomised controlled trial is required to determine 
effectiveness. 
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Background 
Depression contributes to poorer quality of life amongst individuals with psychosis and 
schizophrenia (Saarni et al., 2010). Prevalence rates suggest between 33% and 50% of 
individuals meet criteria for major depression (Whitehead, Moss, Cardno, Lewis & 
Furtado, 2002; Birchwood, Iqbal, Chadwick & Trower, 2000). Depression is associated 
with greater risk of suicide (Drake, Whitaker, Gates & Cotton, 1985), poorer adherence 
to treatment (Conley, 2009), greater interpersonal problems (Rocca et al., 2005) and 
greater insight (Mintz, Dobson & Romney, 2003). Shame is key feature in the emergence 
of depression (Gumley, Braehler, Laithwaite, Macbeth, Gilbert, 2010), where individuals’ 
envisage a bleak future status, through stigma and the loss of social, interpersonal and 
vocational roles (Birchwood et al., 2000). 
 There is a lack of robust evidence supporting the use of antidepressant 
(Whitehead et al., 2002) and psychological (Wykes, Steel, Everitt & Tarrier, 2008) 
interventions for depression in context of schizophrenia. Although there is preliminary 
evidence that depression symptoms improve in people receiving CBT for psychosis 
(CBTp)(Wykes et al., 2008) this important outcome domain is not typically assessed in 
CBTp trials (Jauhar et al., 2014) so there is a need to build the treatment evidence base. 
Acceptance and Commitment Therapy (ACT) could offer a promising psychological 
intervention that helps reduce unhelpful coping strategies including rumination and 
avoidance, and enables committment to behavioural changes consistent with personal 
values. Randomised controlled trials show that ACT reduces depression in non-psychotic 
populations (Hacker, Stone & Macbeth, 2015).  
 Previous non-blind randomised controlled trials investigating ACT for psychosis 
with rehospitalisation as the primary outcome have shown therapeutic promise in US 
acute inpatient settings (Bach & Hayes, 2002; Gaudiano & Herbert, 2006). Gaudiano and 
Herbert (2006) found a small effect of ACT on negative emotion in people with 
psychosis. White et al. (2011) investigated ACT for psychosis with the primary outcome 
focused on emotional distress. They found a significant difference between the ACT and 
Treatment as Usual (TAU) groups for negative symptoms. There was also a trend on the 
limit of significance for differences between the groups in depression (p=0.051) and 
improvement in depression was associated with self-reported increases in mindfulness. 
In a later analysis, White et al. (2015) found that ACT was associated with significantly 
greater likelihood of achieving a clinically significant improvement in depression.  
 To summarise, feasibility research informed the present study that (a) ACT could 
be delivered to outpatients with psychosis and was highly acceptable, (b) that ACT 
appeared to improve symptoms of depression and negative symptoms and (c) that 
improvements in depression were associated with ACT relevant mechanisms of change 
(increased mindfulness skills). Therefore this study was designed as a Pilot Trial (Craig et 
  
 
 
4 
al., 2008) to determine the parameters of a larger, definitive pragmatic multi-centre (UK 
wide) randomised controlled trial of Acceptance and Commitment Therapy for depression 
after psychosis (ACTdp) for individuals with a diagnosis of schizophrenia who also meet 
diagnostic criteria for major depression. In this manuscript we address the following 
questions: 
 
a) What are the potential numbers of participants who fulfil eligibility criteria?  
b) What proportion of potential participants provide fully informed consent to participate 
in the Trial?  
c) What is the overall rate of follow-up in the first 5-months and at 10-months?  
d) What proportion of participants engage with ACTdp? 
e) What rates of improvement in primary (depression) and secondary outcomes (Positive 
and Negative Syndrome Scale and Questionnaire for Personal Recovery) are observed at 
5-month (end of treatment) follow-up and 10-month follow-up?  
f) What are the associations with ACT specific mechanisms (mindfulness skills, 
psychological flexibility) and outcome in terms of depression?  
 
Methods / Design: 
Design:  
The study was a Parallel group Randomised Open Blinded Evaluation (PROBE) of 
Acceptance and Commitment Therapy for depression after psychosis (ACTdp). The study 
protocol was registered before initiating recruitment (ISRCTN: 33306437). The protocol 
was published before treatment codes were broken and data were analysed (Gumley et 
al., 2015). Ethical approval was provided by West of Scotland Research Ethics 
Committee (12/WS/0311). Managerial approval was provided by NHS Greater Glasgow & 
Clyde (GN11CP470).  
 
Participants:  
Participants were consecutively recruited, assessed and randomised. Inpatients or 
outpatients, aged 16 or over and receiving (a) anti-psychotic medication (b) psychiatric 
follow-up and (c) follow-up from a secondary mental health care community based 
services. Participants met DSM-IV-TR criteria for schizophrenia and major depression 
(confirmed by Structured Clinical Interview for DSM / SCID-I & Calgary Depression Scale 
/ CDSS for Schizophrenia; score >7; Kim et al., 2006). Individuals with substance use 
problems were eligible for inclusion but those with significant learning disability, or who 
were unable to speak English were not included. 
 
Entry:  
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Potential participants were identified by their clinical team or by self-referral. Following 
signed informed consent a Research Assistant (RA) conducted baseline assessments. The 
Psychosis and Mood Episodes section of the SCID-I was used to assess diagnostic 
eligibility. Inter-rater reliability for the SCID-I was 90% (range 82-100%).  
 
Randomisation 
Eligible participants were randomised following completion of the baseline assessments. 
Randomisation (at the individual level) was organised at the Robertson Centre for 
Biostatistics, a fully registered and NIHR approved UK Clinical Trials Unit. Randomisation 
was stratified for early (< 2 years duration) versus established psychosis (>2 years 
duration).  
 
Follow-up:  
Participants were assessed at entry pre-randomisation, 5 months and 10-months by a 
blinded RA. All assessments were audio-recorded with consent by the participant. 
Management of blind breaks, inter-rater reliability and safety reporting were governed 
by specifically designed Standard Operating Procedures. 
 
Protecting the Blind:  
RAs entered participant details via a secure web based portal. Following allocation, 
another member of the research group received the outcome of randomisation and 
informed the participant and their treatment team. Blinding was maintained using a wide 
range of measures (e.g. separate offices for therapists and researchers, protocols for 
answering phones, message taking and secretarial support, forbidding any discussions of 
participants between RAs and therapists following randomisation, separate diaries and 
security for electronic randomisation information).  
 
Blind breaks: 
When a blind break occurred, the RA affected informed the Chief Investigator (CI) within 
two working days. In this event a second assessor (blind, where possible, to the 
participant’s allocation) undertook an independent rating of the assessment. Following 
independent rating, assessors met to discuss and resolve any discrepancies. The original 
assessor entered agreed ratings into the Case Record Form (CRF). Where possible, 
another team member, who remained blind to randomisation status, completed the 
remaining assessments for that participant.   
 
Inter-rater reliability: 
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Inter-rater reliability meetings were held on a monthly basis. RAs were trained in all of 
the study measures before commencing data collection. This included observation of a 
live assessment of psychopathology ratings (PANSS, CDSS, SCID) with an experienced 
research assessor. Audio recordings were used for ongoing RA training, secondary 
assessment when blind breaks occurred, and fidelity checking to detect and correct rater 
drift.  
 
Serious Adverse Events: 
In accordance with NIHR trial management standards (Trial Managers' Network, 2014), a 
Serious Adverse Event (SAE) was defined as any occurrence that (a) resulted in death, 
(b) was life threatening, (c) required hospitalisation or prolongation of existing 
hospitalisation, (d) resulted in persistent or significant disability or incapacity, or (e) was 
considered otherwise medically significant by the Chief Investigator.  
 
Primary Outcomes:  
 The Calgary Depression Scale for Schizophrenia (CDSS, Addington, Addington & 
Schissel, 1990) assessed severity of depression. The CDSS was better the BDI, PANSS – 
Depression subscale, and HAM-D for both sensitivity (94%) and specificity (89%) of 
SCID Depression diagnosis (Kim et al., 2006). Inter-rater reliability for the CDSS was 
92% (range 67-100%). In this study the Intraclass Correlation Coefficient was ICC=0.68 
(95%CI, 0.46-0.82). 
 The Beck Depression Scale (BDI-II; Beck et al., 1996) was used as a well-
established self-report measure of depression with excellent reliability and validity. In 
this study Cronbach’s Alpha was 
  
a=0.90. 
 
 
Therapy Mechanisms:  
 The Kentucky Inventory of Mindfulness Skills (KIMS; Baer et al., 2004) was used 
to assess four mindfulness skills: observing, describing, acting with awareness, and 
accepting without judgement. The KIMS has good internal consistency, test retest 
reliability and construct validity. 
 Psychological flexibility was assessed with the 7 item version of the Acceptance 
and Action Questionnaire (AAQ-II; Bond et al., 2011). This measure has satisfactory 
structure, reliability, and validity.  
 
Secondary Outcomes: 
 The Positive and Negative Syndrome Scale (PANSS; Kay, Fiszbein & Opler, 1987) 
was used to measure psychiatric symptoms. We adopted the 5-factor model that yields 
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scores for positive, negative, disorganisation, excitement and emotional distress 
symptoms (van der Gaag et al., 2006). Inter-rater reliability for the PANSS in this trial 
was 83% (range 63 – 97%). 
 The Process of Recovery Questionnaire (QPR; Neil et al., 2009) was used to 
measure service user rated recovery. The QPR has two subscales measuring 
intrapersonal tasks and interpersonal factors relevant to personal recovery and has 
excellent reliability and validity. 
 
Treatments: 
Acceptance and Commitment Therapy for depression after psychosis (ACTdp):  
 Individuals received up to 5 months of individual ACTdp. ACTdp is based on the 
rationale that the experience of psychosis can threaten progress in valued life domains.  
The ACTdp intervention protocol was used to enhance engagement with valued life 
activities through values clarification, increasing mindfulness and psychological flexibility 
and reducing experiential avoidance and fusion with experiences. An individual 
formulation based on the six ACT core processes was developed for each participant in 
the treatment arm. Fidelity of treatment strategy use and consistency with the ACT 
model were determined via weekly supervision by a senior clinician. The details of 
intervention has been described in greater detail elsewhere (Gumley et al., 2015; White, 
2014).  
 
Standard Care (SC):  
 Treatment received by all participants in the trial was examined in order to 
establish the parameters of Standard Care. For inclusion, all participants had to be in 
receipt of antipsychotic medication and follow-up from a secondary specialist mental 
health service. 
 
Statistical Analyses:  
 As a pilot study we aimed to assess the variability in the outcome data and look 
for suggestive trends in order to estimate parameters for a definitive multi-site RCT. To 
this end, we planned exploratory repeated measures regression models, adjusting for 
baseline measures including the stratification variable to be fitted to assess treatment 
effects on the main outcome measures and the evolution of these treatment effects over 
time and to estimate residual variability. We aimed to explore outcome measures for 
strong treatment signals. Therefore we report both ITT and Per Protocol Sample (PPS). 
 
Results: 
Population 
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The flow of participants into the study is described in Figure 1. We identified 92 potential 
participants of whom 55 were referred to the study. Of this group, 38 gave their 
informed consent to enter the study and 7 were not eligible. Two participants, who 
initially gave their informed consent subsequently changed their mind before 
randomization. This left 29 participants who were fully assessed before being 
randomized to ACTdp+SC (n=15) or SC alone (n=14). In terms of follow-up of 
ACTdp+SC, two participants declined follow-up at 5-months and we were unable to 
follow-up 1 further participant at 10-months. In SC, 1 participant declined follow-up at 
10-months.  
 
Insert Figure 1 about here 
 
 The characteristics of the final sample are described in Table 1 below. The sample 
were on average 46.5 years old, male (n=19, 65.5%), white Scottish (n=27, 93.1%) 
with on average 13.2 years of education.  
 
Insert Table 1 about here 
 
 During the trial we observed 7 Serious Adverse Events (SAEs). All SAEs were 
related to Hospitalization, 2 (13.3%) were in the ACTdp+SC group and 5 (35.7%) in the 
SC group. There were 14 unblindings during the trial. Of these 11 (73.3%) were in the 
ACTdp+SC group and 3 (21.4%) were in SC. All unblindings were rated by another 
Researcher masked to treatment allocation and subsequent follow-ups were blind rated. 
 
Intervention 
On average 17.4 (s.d.=5.9) ACTdp sessions were scheduled, and 15.4 (s.d.=6.2) were 
attended by participants. Of the remaining sessions, 0.7 (s.d.=1.4) were cancelled and 
1.2 (s.d.=1.5) not attended. The number of participants attending 10 or more sessions 
(our a priori definition of an adequate number of sessions) was 10 (71.4%).  
 
Outcomes 
The outcomes of depression measured by CDSS and BDI are described in Table 2 below. 
We did not observe significant differences between groups on the CDSS total score at 5-
months (Coeff=-1.43, 95%CI -5.17,2.32, p=0.45) or at 10-months (Coeff=1.8, 95%CI -
2.10, 5.69, p=0.36). Outcomes Per Protocol Sample (PPS) did not differ from ITT 
analysis. In terms of BDI, we noted a statistically significant effect in favour of 
ACTdp+SC at 5-months (Coeff=-8.38, 95%CI -15.49, -1.27, p=0.02) but not at 10-
months (Coeff=-4.85, 95%CI -12.10, 2.39, p=0.18). In the PPS analyses we noted 
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sustained outcomes in favour of ACTdp+SC at both 5-months (Coeff=-10.18, 95%CI -
17.69, -2.68, p=0.01) and 10-months (Coeff=-8.11, 95%CI -15.62, -0.60, p=0.04). 
 
Insert Table 3 about here 
 
 The outcomes for AAQ and KIMS are described in Table 3. We observed a 
significant effect in favour of ACTdp+SC in terms of improved psychological flexibility 
(reduced AAQ score) at 5-months follow-up (Coeff=-0.883, 95%CI -14.94, -2.71, 
p<0.01) but not at 10-months (Coeff=-4.92, 95%CI -11.09, 1.25, p=0.11). In the PPS 
analysis outcomes at 5-months (Coeff=-10.71, 95%CI -16.16, -5.26, p=0.0004) and 10-
months (Coeff=-6.27, 95%CI -11.72, -0.82, p=0.03).  
 In terms of KIMS subscales we observed the following outcome signals. At 10-
months significant outcomes in favour of ACTdp+SC were noted for KIMS Observing 
(Coeff=4.94, 95%CI 0.47, 9.41, p=0.03) and KIMS Total (Coeff=10.91, 95%CI 0.22, 
21.60, p=0.05). In the PPS analysis significant effects in favour of ACTdp+SC were 
noted for KIMS Accepting at 5-months (Coeff=4.78, 95%CI 0.68, 8.88, p=0.02) and 10-
months (Coeff=5.39, 95%CI 1.29, 9.40, p=0.01) and KIMS Total at 5-months 
(Coeff=9.44, 95%CI 0.07, 18.82, p=0.05) and 10-months (Coeff=12.63, 95%CI 3.25, 
22.00, p=0.01). 
 
Insert Table 3 about here 
 
Secondary Outcomes 
We did not observe any other effects on outcomes using the Questionnaire for Personal 
Recovery and the Positive and Negative Syndrome Scale with one exception which was 
that there was a significant effect in favour of ACTdp+SC on PANSS Cognitive 
Disorganisation (Coeff=-4.92, 95%CI -8.50, -1.35, p=0.01) and PANSS Excitement at 5-
months (Coeff=1.98, 95%CI -3.60, -0.35, p=0.019). In the PPS analyses we noted 
significant effects in favour of ACTdp+SC for PANSS Negative (Coeff=-4.03, 95%CI -
10.01, -2.30, p=0.04), PANSS Cognitive Disorganisation (Coeff=-6.16, 95%CI -15.49, -
1.27, p=0.003), PANSS Emotional Distress (Coeff=-2.46, 95%CI -4.74, -0.18, p=0.04) 
and PANSS Total (Coeff=-12.45, 95%CI -23.11, -1.80, p=0.02) at 5-months.  
 
Mechanisms of Change 
In order to investigate hypothesized mechanisms of change we calculated change scores 
at 5-months and 10-months for the CDSS, BDI, KIMS and AAQ. We then investigated 
associations between changes in depression and changes in mindfulness and 
psychological flexibility. Table 4 below summarizes the observed correlations at 5-
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months and 10-months. Consistent with the lack of observed effects on CDSS we 
observed no significant associations between depression and hypothesized mechanisms 
of change at either 5 or 10-months. With respect to changes in BDI we observed 
significant correlations with changes in psychological flexibility at 5-months 
(r=0.55,p<0.01) and 10-months (r=0.41,p<0.05). Furthermore, we observed significant 
associations between KIMS Observing (r=-0.58,p<0.01), KIMS Describing (r=-
0.63,p<0.01), KIMS Awareness (r=-0.41,p<0.01) and change in BDI at 5-months. 
Finally we observed as significant association between KIMS Describing (r=-
0.49,p<0.01), KIMS Awareness (r=-0.53,p<0.01), KIMS Acceptance (r=-0.49,p<0.01) 
and change in BDI at 10-months. 
 
Insert Table 4 about here  
 
Discussion: 
This is the first randomised controlled trial of any psychological therapy in psychosis that 
specified depression as a primary outcome. We sought to map the parameters for a 
larger scale definitive trial of ACT for depression after psychosis. Our primary concern 
was the identification of outcome signals in relation to depression (CDSS, BDI-II), and 
established therapy mechanisms (KIMS and AAQ) as a basis to estimate the power and 
sample size requirements for a future trial. Over a period of 12-months recruitment, we 
received 92 potential enquiries, converting to 55 participant referrals (referrals 4.6 per 
month) leading to 29 (2.4 per month) randomisations. Over 10-months we retained 25 
(86.3%) of participants in follow-up.  
 One of the key challenges for the study was the identification and recruitment of 
potential participants. Depression co-occurring with psychosis was not routinely 
identified by mental health staff. Positive symptoms tended to be prioritised for 
monitoring and assessment, there was poor discrimination between negative symptoms 
and depression, potential participants rarely reported depressed mood (despite severe 
symptoms on the BDI-II), and conversations about depressed mood and hopelessness 
were frequently avoided. In a future large-scale trial, supporting mental health staff with 
knowledge and skills to detect and respond to depression in this group would increase 
recruitment. Our results also point to the need to develop pathways to enhance self-
referral for the assessment and treatment of depression. This is particularly important 
given the role of depression in reduced quality of life and serious adverse outcomes such 
as death by suicide (Foster, 2015; Pompili, Lester, Innamorati, Tatarelli, & Girardi, 
2008).  
 The ACTdp intervention was well tolerated. On average participants received 15 
sessions over 5-months, rates of cancellation and non-attendance were low and 70% 
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received at least 10-sessions of therapy. 
 Although the study was not powered or designed as an efficacy or effectiveness 
trial we did wish to explore treatment signals and we had established a priori primary 
outcomes, therapy specific outcomes, and secondary outcomes. We did not observe any 
change signals on the CDSS. We noted a statistically significant improvement in BDI-II 
for the ACTdp+SC group at 5-months but not at 10-months. We noted a between group 
Cohen’s Effect Size of r=0.67 at 5-months end of treatment and r=0.31 at 10-months. 
These effects compare well with those identified in a recent meta-analysis (Hacker, 
Stone & Macbeth, 2015, In Press) who found that studies investigating ACT for 
depression as a primary treatment target (n=12 studies comprising n=674 participants) 
suggested also large significant between group effect size (d= .73, p<.001). For ACT 
versus active control conditions (n=15 studies comprising n=755 participants) findings 
suggested a small non-significant between groups effect size (d=.26, n.s.) 
Consistent with the model of therapeutic change in ACT and with earlier 
observations (White et al., 2011; White et al., 2013) we observed statistically significant 
changes in psychological flexibility and mindfulness. We noted significant associations 
between psychological flexibility at both 5 and 10-month follow-up using the BDI and 
associations between changes in mindfulness and depression at 5 and 10-month follow-
up. Given this replication of earlier findings we propose that the strongest signals in 
relation to ACTdp relate to measures of self reported depression, psychological flexibility 
and mindfulness. Although lack of change in objective measures of symptom severity 
have been reported in previous trials of ACTp (e.g. Bach & Hayes, 2002) lack of any 
signal on any observer based measures in our study is an important consideration.  
We would also argue for the additional inclusion of behaviourally based measures 
of functioning. This would be in keeping with the goals of ACTdp to increase behavioural 
activation through engagement in valued activities. A future large-scale trial could 
include the measurement of daily activities as a key outcome.  In their trial of Social 
Recovery CBT (CBTsr) in first episode psychosis, Fowler et al. (2009) used the Time Use 
Survey (Short, 2006) as an interview based measure of hours spent in ‘Constructive 
Economic Activity’ and in ‘Structured Activity’. The pilot study data showed signals 
suggesting that compared to TAU CBTsr was associated with improved economic activity 
(increase of 4.4 hours versus 3.2 hours) and improved structured activity (12.0 hours 
versus 4.1 hours). These measures can also be supplemented by use of objective 
measures of physical activity such as ActiGraphy. For example, using actigraphic 
measurement of daytime routines Wichniak et al (2011) found that in people with 
schizophrenia, higher rates of depression were associated with lower rates of physical 
activity and longer time spent in bed. This is a highly relevant outcome as a lack of 
physical and leisure time activity is linked to poorer quality of life in schizophrenia 
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(Vancampfort et al., 2011).  
Our study had some noteworthy limitations. First, the sample size of 29 was 
small. But, the 11 randomized controlled trials included in the Whitehead et al. (2002) 
Cochrane Review of antidepressants in schizophrenia all randomized n<30 participants. 
Of the 5 RCTs of ACTp (Back & Hayes, 2002; Gaudiano & Herbert, 2006; White et al., 
2011; Shawyer et al., 2012; Gaudiano et al., 2015) the mean sample size is 40.6 (range 
13-80). Gaudiano et al. (2015) conducted a randomized controlled trial of an ACT based 
treatment package for people with affective psychoses (mostly major depression with 
psychotic features) and found medium to large effects for of ACT on depression and 
psychosocial functioning. The study sample size was n=13, randomization was not 
independent of trial team and assessment of outcome was unblinded. Taken together 
these findings indicate a need for large scale, well-designed methodologically rigorous 
trials targeting depression in the context of psychosis. A second limitation is that 
although our trial was blinded, our rates of unblinding were high in the ACTdp+SC group. 
Our RAs were instructed to remind both staff and participants about the importance of 
blinding. In addition, separate office facilities, an independent randomization procedure 
that protected the blind, banning discussions regarding participants between RAs and 
Trial Therapists were instituted throughout the trial. Despite this, the source of 
unblindings was participants and less frequently health service staff. Where an 
unblinding occurred we were able to allocate an alternative blinded researcher to 
undertake subsequent follow-up assessments. In addition, since all assessments were 
audio recorded (with consent) we were able to subject unblinded assessments to 
independent verification of symptoms severity. Finally, our approach to recruitment was 
informed by an earlier feasibility trial of ACT for emotional distress in psychosis (White et 
al., 2011). A clear signal emerging from the trial was a change in depression amongst 
those participants receiving ACT (White et al., 2013; White et al., 2015).  
 Depression is a major contributor to loss of quality of life in schizophrenia and 
other psychotic disorders (Saarni et al., 2010) and is a clear risk factor for suicide 
(Drake, Whitaker, Gates & Cotton, 1985). Depression has been associated with poorer 
adherence to treatment (Conley, 2009), longer duration of untreated psychosis (Drake et 
al., 2003), greater problems in family relationships (Rocca et al., 2005), poorer 
interpersonal functioning (Rocca et al., 2005), and greater experiences of stigma 
(Angermeyer et al., 2004). The development of future large scale generalizable 
randomised controlled trials to improve depression and functioning in people with 
schizophrenia and other psychoses is clearly merited. ACT is one clear candidate 
treatment that has the potential to improve engagement with valued life goals and 
activities alongside feelings of depression and demoralization. 
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